

In one aspect, the present disclosure provides use of an anti-IL-23A antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 18 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 in the manufacture of a medicament for the treatment of psoriasis in a patient, wherein:

- a) a first dose of 150 mg of said anti-IL-23A antibody is to be administered to the patient;
- b) a second dose of 150 mg of said anti-IL-23A antibody is to be administered to the patient 4 weeks after administration of said first dose; and
- 5 c) a first maintenance dose of 150 mg of said anti-IL-23A antibody is to be administered to the patient 12 weeks after administration of said second dose.

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 4 to 24 weeks, for example 4 to 16 weeks, for example 4 to 12 weeks, after said initial dose is administered; and

In one embodiment, the present disclosure provides a method for treating an inflammatory disease, for treating psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA, comprising administering to a patient an anti-IL-23A antibody, said method

5 comprising:

- a) administering an initial dose of the anti-IL-23A antibody to the patient;
- b) administering a first maintenance dose of the anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered; and
- c) administering at least one additional maintenance dose to the patient 4 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

- a) administering an initial dose of said anti-IL-23A antibody to the patient;
- b) administering a loading dose of said anti-IL-23A antibody to the patient 4 weeks after said initial dose is administered;
- c) administering a first maintenance dose of said anti-IL-23A antibody to the patient 6 weeks after said loading dose is administered; and
- d) administering at least one additional maintenance dose to the patient 6 weeks after said first maintenance dose is administered.

In one embodiment, in said method, the initial dose, the loading dose and the maintenance dose comprise 150 mg of said anti-IL-23A antibody.

In another aspect, the present disclosure provides use of an anti-IL-23A antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 18 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 in the manufacture of a medicament for the treatment of psoriasis in a patient, wherein the medicament comprises 150 mg of the anti-IL-23A antibody.

In one embodiment, the present disclosure further provides a method for treating an inflammatory disease comprising administering to a patient 15 to 300 mg, for example 15 to 250 mg, for example 90 to 180 mg, of an anti-IL-23A antibody. In one embodiment, the inflammatory disease is psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and non-radiographic ax-SpA.

In one embodiment, the method comprises administering to a patient 70 to 90 mg, 80 to 100 mg, 90 to 110 mg, 100 to 120 mg, 110 to 130 mg, 120 to 140 mg, 130 to 150 mg, 140 to 160 mg, 150 to 170 mg, 160 to 180 mg, 170 to 190 mg, 180 to 200 mg, 190 to 210 mg, 200 to 220 mg, 210 to 230 mg, 220 to 240 mg, 230 to 250 mg, 240 to 260 mg, 250 to 270 mg, 260 to 280 mg, 270 to 290 mg or 280 to 300 mg of an anti-IL-23A antibody.

In one embodiment, in any one of the methods above, the method is for treating moderate to severe chronic plaque psoriasis, for example in a patient who is a candidate for systemic therapy or phototherapy.

In one embodiment, in any one of the methods above, the method is for treating moderate to severe chronic plaque psoriasis, for example in a patient who failed to respond to, or who has a contraindication to, or is intolerant to other systemic therapy including ciclosporin, methotrexate, psoralen or ultraviolet-A light (PUVA)

In one embodiment, in any one of the methods above, the method is for treating pustular psoriasis.

- 5 In one embodiment, in any one of the methods above, the method is for treating erythrodermic psoriasis (also known as psoriatic erythroderma).

In one embodiment, in any one of the methods above, the method is for treating psoriatic arthritis, for example active psoriatic arthritis.

10

In one embodiment, the anti-IL-23A antibody is used alone or in combination with one or more non-biologic DMARDs (Disease-Modifying Antirheumatic Drug), for example for treating psoriatic arthritis, for example active psoriatic arthritis, for example to reduce signs and symptoms. In one embodiment, the anti-IL-23A antibody is used or indicated

15

to inhibit the progression of structural damage, and/or improve physical function.

In one embodiment, the anti-IL-23A antibody is used alone or in combination with methotrexate (MTX), for example for the treatment of psoriatic arthritis, for example active psoriatic arthritis, for example when the response to previous non-biological DMARD therapy has been inadequate. In one embodiment, the anti-IL-23A antibody is used to reduce the rate of progression of peripheral joint damage as measured by X-ray and/or to improve physical function.

Claims

1. Use of an anti-IL-23A antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 18 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 in the manufacture of a medicament for the treatment of psoriasis in a patient, wherein:

- a) a first dose of 150 mg of said anti-IL-23A antibody is to be administered to the patient;
- b) a second dose of 150 mg of said anti-IL-23A antibody is to be administered to the patient 4 weeks after administration of said first dose; and
- c) a first maintenance dose of 150 mg of said anti-IL-23A antibody is to be administered to the patient 12 weeks after administration of said second dose.

2. The use according to claim 1, wherein:

maintenance doses of 150 mg of said anti-IL-23A antibody are to be administered to the patient every 12 weeks after administration of said first maintenance dose.

3. The use according to claim 1 or 2, wherein said psoriasis is moderate to severe chronic plaque psoriasis.

5 4. The use according to any one of claims 1 to 3, wherein said anti-IL-23A antibody is to be administered by subcutaneous administration.

5. The use according to any one of claims 1 to 4, wherein the patient achieves a Psoriasis Area and Severity Index (PASI) score of 50 (PASI 50).

10

6. The use according to any one of claims 1 to 4, wherein the patient achieves a PASI score of 75 (PASI 75).

7. The use according to any one of claims 1 to 4, wherein the patient achieves a PASI

15

8. The use according to any one of claims 1 to 4, wherein the patient achieves a PASI score of 100 (PASI 100).

9. Use of an anti-IL-23A antibody comprising a light chain comprising the amino acid sequence of SEQ ID NO: 18 and a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 in the manufacture of a medicament for the treatment of psoriasis in a patient, wherein said medicament comprises 150 mg of said anti-IL-23A antibody.
10. The use according to claim 9, wherein said psoriasis is moderate to severe chronic plaque psoriasis.
11. The use according to claim 9 or 10, wherein said anti-IL-23A antibody is to be administered by subcutaneous administration.
12. The use according to any one of claims 9 to 11, wherein the patient achieves a PASI score of 50 (PASI 50).
13. The use according to any one of claims 9 to 11, wherein the patient achieves a PASI score of 75 (PASI 75).
14. The use according to any one of claims 9 to 11, wherein the patient achieves a PASI score of 90 (PASI 90).
15. The use according to any one of claims 9 to 11, wherein the patient achieves a PASI score of 100 (PASI 100).